

AUG. 26. 2004 12:08PM

GW GLOBAL R&D IS

NO. 8535 P. 1/20

RECEIVED  
CENTRAL FAX CENTER

AUG 26 2004

**FACSIMILE COVER SHEET**

*GlaxoSmithKline*  
Corporate Intellectual Property  
5 Moore Drive, Research Triangle Park  
Durham, NC 27709

To: Examiner DAVID LUKTON  
Company/Division: USPTO  
Phone: 571/272-0952  
Fax: 703/872-9306

From: J. Michael Strickland  
Company/Division: *GlaxoSmithKline*  
Phone: 919-483-9024  
Fax: 919-483-7988

Date: August 26, 2004  
Pages to follow: 19

*This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable federal or state law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited.*

**Subject: Combined Amendment & Petition for Ext. of Time Under 37 CFR 1.136(a) & Amendment**

RE: Response to Office Action of April 29, 2004  
Applicant of: ARMOUR, Duncan Robert, et. al.  
U.S. Serial No.: 09/868,395 Filed: 09/06/2001  
Title: COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY  
DISEASES  
Art Unit: 1653  
Attorney Docket No.: PG3612USW

**Attached:**

1. Certificate of Transmission (37 CFR 1.8(a))
2. Combined Amendment & Petition for Extention of Time Under 37 CFR 1.136(a)
3. Amendment

8/26/2004 - This is being re-sent to replace  
previous fax sent this day which was one  
page shy of full document (when I rec'd  
my fax receipt back.)

*Thank you,  
Joyce Hartnett*

<b>CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)</b>				Docket No. PG3612USW
Applicant(s): <b>ARMOUR, Duncan Robert, et. al.</b>				
Application No. 09/868,395	Filing Date 09/06/2001	Examiner David Lukton	Group Art Unit 1653	
Invention: <b>COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES</b>				
<p>I hereby certify that this <u>Combined Amendment &amp; Petition for Ext. of Time Under 37CFR 1.136(a) &amp; Amendment</u> <small>(Identify type of correspondence)</small> is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703/872-9306</u></p> <p>on <u>August 26, 2004</u> <small>(Date)</small></p> <p style="text-align: right;">_____ <b>Joyce Hartnett</b> <small>(Typed or Printed Name of Person Signing Certificate)</small>  <small>(Signature)</small></p>				

P10/REV02

<b>COMBINED AMENDMENT &amp; PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Large Entity)</b>					Docket No. <b>PG3612USW</b> <b>RECEIVED</b> CENTRAL FAX CENTER
In Re Application Of: <b>ARMOUR, Duncan Robert, et. al.</b>					
<b>AUG 26 2004</b>					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/868,395	09/06/2001	David Lukton	23347	1653	8883
<b>Invention: COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES</b>					
<u><b>COMMISSIONER FOR PATENTS:</b></u>					
<p>This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of <u>April 29, 2004</u> in the above-identified application.</p>					
<p>The requested extension is as follows (check time period desired):</p>					
<input checked="" type="checkbox"/> One month <input type="checkbox"/> Two months <input type="checkbox"/> Three months <input type="checkbox"/> Four months <input type="checkbox"/> Five months					
from: <u>July 29, 2004</u> <i>Date</i>		until: <u>August 29, 1004</u> <i>Date</i>			
<p>The fee for the amendment and extension of time has been calculated as shown below:</p>					
<b>CLAIMS AS AMENDED</b>					
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	20	27 = 0	x \$18.00	\$0.00	
INDEP. CLAIMS	5	5 = 0	x \$86.00	\$0.00	
<b>FEE FOR AMENDMENT</b>					<b>\$0.00</b>
<b>FEE FOR EXTENSION OF TIME</b>					<b>\$110.00</b>
<b>TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME</b>					<b>\$110.00</b>

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Large Entity)**

 Docket No.  
**PG3612USW**

 RECEIVED  
 CENTRAL FAX CENTER

**AUG 26 2004**

The fee for the amendment and extension of time is to be paid as follows:

A check in the amount of \_\_\_\_\_ for the amendment and extension of time is enclosed.

Please charge Deposit Account No. **07-1392** in the amount of **\$110.00**

The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. **07-1392**

- Any additional filing fees required under 37 C.F.R. 1.16.
- Any patent application processing fees under 37 CFR 1.17.

If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. \_\_\_\_\_.

Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**



Signature

J. Michael Strickland  
 Registration No.: 47,115  
 GlaxoSmithKline  
 Corporate Intellectual Property  
 Five Moore Drive  
 P.O. Box 13398  
 Research Triangle Park, NC 27709-3398  
 Tel.: 919/483-9024 Fax: 919/483-7988

CC:

 Dated: August 26, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)].  
 (Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

P28LARGE/REV04